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cells and leukemia cells. Its narrow tissue distribution, sub

strate speci?city, and close homology to other cell membrane
transporters make OCT6 an attractive target for the treatment

of myeloid diseases.
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ORGANIC CATION TRANSPORTER
PREFERENTIALLY EXPRESSED IN
HEMATOPOIETIC CELLS AND LEUKEMIAS
AND USES THEREOF

porter With a Km for MTX betWeen approximately 08-26

uM. Decreased RFC activity has been observed in several in
vitro models of transport-mediated MTX resistance (Bio
chem. Pharmacol. 11: 1233-1234, 1960). Once rodent and
human genes encoding proteins With RFC activity Were iso
lated, the molecular explanations for decreased RFC activity
emerged. RFCl transfection into the transport-de?cient

CROSS REFERENCE TO RELATED
APPLICATIONS

MTXR ZR75 cell line resulted in a 20-fold increase in 6-hour
MTX uptake and a concomitant 250-fold increase in sensi

This application is a divisional application of and claims

the bene?t of application Ser. No. 10/849,551, ?led May 20,

tivity to MTX relative to control cell clones, shoWing that the
RFCl gene reconstitutes RFC activity and has a signi?cant
impact on MTX cytotoxicity (MoscoW, et al., Cancer Res. 55:

2004 noW abandoned, Which claims the bene?t of US. Pro

visional Application No. 60/471,709, ?led May 20, 2003.

3790-3794, 1995).
FIELD OF THE INVENTION

In different cell lines, MTX transport de?ciency has been
ascribed either to mutations in the RFC gene or in decreased

The invention relates to a gene encoding an organic cation
transporter, OCT6, and its use as a target for the treatment of

expression of the RFC gene product. Several studies have
demonstrated that RFCl gene expression is an important

hematological malignancies, and in particular, leukemia. The

determinant of sensitivity to MTX. In in vitro studies, We have
found that RFCl RNA levels correlate With MTX sensitivity
in a panel of non-selected cell lines, including breast cancer

invention further relates to screening methods for identifying

agonists and antagonists/binding partners of OCT6 transport

20

activity.

cell lines (MoscoW et al., Int] Cancer. 72: 184-190, 1997).
A plethora of genes With the ability to transport MTX out of

BACKGROUND OF THE INVENTION

The lipid bilayer of the cellular membrane insulates the

25

intracellular milieu from exposure to hydrophilic com

pounds. Unlike lipophilic compounds that can diffuse
through cellular membranes, Water-soluble compounds usu
ally require speci?c transport mechanisms to gain access to
the intracellular space. The regulation of the tra?ic of polar

HoWever, despite the multitude of MTX export genes, clinical
studies have shoWn a relationship betWeen the expression of
RFCl, the mechanism of MTX uptake, and prognosis in
30

compounds in both directions across the cellular membrane is

a complex process involving several large families of trans

port proteins.
Most often in cancer research, drug transport is thought of
as a mechanism of cellular drug resistance, as drug e?lux
pumps such as the products of the MDR1 and MRP genes
have been shoWn to be mechanisms of resistance to lipid

35

Acute Lymphoid Leukemia (ALL) and osteosarcoma. As a
result, RFCl expression and MTX uptake are noW implicated
as determinants of clinical sensitivity in several types of
tumors. Thus, the role of RFCl in mediating sensitivity of its
cytotoxic drug substrates has become a prototype that illus
trates the potential role of transporters, like OAT and OCT
genes, in determination of anticancer drug selectivity and

toxicity.
HoWever, there is a need to identify additional channels, or
transporters, that are found in speci?c cancers, to enable the
targeting of different cancers With anticancer agents that are

soluble anticancer drugs. HoWever, drug transport is a tWo
Way street, and mechanisms also exist for pumping drugs into

cells. Forpolar, Water-soluble anticancer agents, drug uptake,

the cell have been reported, including MRP1, MRP2, MRP3,
MRP4, the organic anion transporters hOAT2 and hOAT3,
and the mitoxantrone-resistance protein (BCRP/MXR).

40

and not drug ef?ux, is the critical determinant of cellular drug

substrates for those transporters.

accumulation.

SUMMARY OF THE INVENTION

Most cancer chemotherapy employs drugs that are lipid
soluble that can easily penetrate the cell membrane of cancer

cells. One advantage of using lipid-soluble drugs is that they

45

easily gain intracellular access to different types of cancer
cells, so many cancer cells appear to be initially sensitive to
these drugs. The disadvantage is that cancer cells learn to
increase the activity of drug ef?ux pumps in the cell mem

brane to pump lipid-soluble drugs out of the cell, resulting in

the organic cation transporter (OCT) family (SLC22 gene
50

drug resistance.
In contrast, potential Water-soluble anticancer drugs may
not survive the preclinical screening process since there is a
55

OCT6 transporter. The method involves contacting a cell

60

The importance of carrier-mediated anticancer drug uptake

The major mechanism of MTX uptake at pharmacologic con
centrations is the reduced folate carrier (RFC), an OAT trans

In another aspect of the present invention there is a method

Which overexpresses an OCT6 transporter gene With a test

is exempli?ed in reduced folate carrier (RFC) mediated
uptake of methotrexate (MTX). Methotrexate (MTX), a
reduced folate analogue, is scavenged and retained in cells by
mechanisms designed to secure folates from the environment.

mia, leukemia blast cells and CD34+ cells.
In one aspect, the present invention provides a novel target
for hematological malignancies such as leukemia, an OCT6

for screening potential substrates that selectively bind the

polar, Water-soluble drugs. One approach to more effectively
utiliZe Water-soluble anticancer drugs is to identify Which of
the doZens of transport genes are actually expressed in
tumors.

family). Tissue distribution of this protein is distinct from
other OCT protein family members; being detected in leuke

transporter.

great deal of variability in the expression of drug transport
genes in different types of cancer cells. Variability in transport
gene expression may result in variability in accumulation of

The present invention is directed toWards a membrane pro
tein that functions to transport hydrophilic substances across
cellular membranes. The protein, OCT6, is a neW member of

compound and determining Whether the test compound is a
substrate for the OCT6 transporter.
In another aspect, there is a method for screening potential
anti-cancer agents in a cell overexpressing an OCT6 trans

porter gene. The method comprises determining viability of a
65

cell Which expresses OCT6 transporter gene incubated in the
presence and absence of a test compound and identifying the
test compound as a potential anti-cancer agent if there is
cellular in?ux of the test compound and cell death.

US 7,723,019 B2
4

3

actin RNA, as a control for equivalence of mRNA template.
The units, in log scale, are arbitrary and based on a standard
curve of OCT6 RT-PCR in serially diluted HL60 RNA. Unity
is de?ned as the level of OCT6 RNA found in MOLT4 cells.
FIG. 5. shoWs quantitative RT-PCR for the gene OCT6
using RNA extracted from leukemic blasts obtained from
patients at the time of initial diagnosis. OCT6 levels Were
normaliZed to the expression of actin RNA, as a control for
equivalence of mRNA template. The OCT6 RNA levels in
placenta, liver, kidney and MOLT-4 cell line Were determined

In another aspect of the invention, a test kit is provided for

screening candidate drugs for hematologic malignancies
comprising a mammalian cell line or cells Which overexpress
OCT6, a control substrate and a detectable substance.
In still another aspect of the invention, there are immuno

genic compositions for treating hematological malignancies.
In a preferred embodiment, immunogenic compositions for
treating leukemia comprise a substrate that binds selectively
to a leukemia cell expressing the OCT6 transporter gene. In

another preferred embodiment of the invention, the substrate
comprises an antibody that selectively binds to the OCT6

concurrently and shoWn for comparison. The units, in log

transporter protein. Preferably, the OCT6 transporter protein

scale, are arbitrary and based on a standard curve of OCT6

alloWs cellular uptake of the substrate Which then causes cell
death. In one embodiment the substrate is cytotoxic and in
another preferred embodiment the substrate is coupled With a

RT-PCR in serially diluted HL60 RNA. Unity is de?ned as the
level of OCT6 RNA found in MOLT4 cells.

cytotoxic agent.
In still another aspect, the present invention provides a
method for impairing a leukemia cell comprising contacting
the cell With a cytotoxic OCT6 transporter protein. In one
embodiment the substrate is a cytotoxin and in another
embodiment the substrate is coupled to a cytotoxic agent.
In yet another aspect, the present invention provides a

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery and isola
tion of a neW member of the SLC22 gene family (the OCT
20

method for treating hematological malignancies comprising
administering to a subject in need thereof an immunogenic
composition comprising a substrate that binds selectively to a
cell expressing the OCT6 transporter gene. In a preferred

this transporter Were found in some leukemia cell lines, in
25

embodiment the OCT6 transporter protein alloWs cellular

CD34+ cells, and in circulating leukemia blast cells.
All patents, patent applications and literature cited in this
description are incorporated herein by reference in their
entirety. In the case of inconsistencies, the present disclosure,

including de?nitions, Will prevail.

uptake of the substrate Which then causes cell death. In

another preferred embodiment the substrate is cytotoxic. In
another preferred embodiment, the substrate is coupled With
a cytotoxic agent.

family of proteins) that is unusual for its distinct pattern of
tissue distribution. Rather than the typical high levels of
expression in liver, kidney or placenta, high levels of RNA for

30

OCT Family

OCT6.

TWo families of proteins involved in maintaining homeo
stasis of charged organic compounds are the organic anion
transporters (OATs) Which carry the SLC21 designation and
the organic cation transporters (OCTs), Which carry the
SLC22 designation (See Table 1). OATs and OCTs each have
characteristic patterns of tissue expression, With predominant

FIG. 1. B. is a dendrogram shoWing phylogenic relation
ship betWeen OCT6 (SEQ ID NO:2) and other OCT and OAT

i.e., liver, kidney or placenta.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. A. shoWs the predicted hydropathy pro?le of

proteins, including, OCTN1 (SEQ ID NO:4), OCT3 (SEQ ID
NO:5), OCTN2 (SEQ ID NO:6), OCT2 (SEQ ID NO:7),
OCT1 (SEQ ID NO:8), OAT5 (SEQ ID NO:9), OAT4 (SEQ
ID NO:10), OAT3 (SEQ ID NO:11), and OAT1 (SEQ ID

35

expression in a tissue involved in the transport of xeriobiotics,

TABLE 1

40

Organic anion and cation transported genes

NO:12).

Gene Family Gene Name

FIG. 2A-F. is the CLUSTLAW alignment of OCT6 and
other OCT and OAT proteins. The bottom roW represents

SLC21
45

areas of consensus.

Locus Link Alternative Names

SLC21A1
SLC21A2

6577
6578

SLC21A3

6579

SLC21A4
SLC21A5
SLC21A6
SLC21A7

28237
28236
10599
28235

SLC21A8

28234

LST2, OATP8, SLC21A8,

SLC21A9
SLC21A10
SLC21A11

11309
28233
28232

OATP-8
OATP-B
OATP4
OATP-D

determined by RT-PCR using a cDNA panel. Only 1000><
(highest) cDNA concentration is shoWn. Panel A. 1, salivary
50

marroW; 11, fetal brain; 12, fetal liver. Panel B. 1, brain; 2,

heart; 3, kidney; 4, spleen; 5, liver; 6, colon; 7, lung; 8, small
intestine; 9, muscle; 10, stomach, 11, testis; 12, placenta.
FIG. 4. shoWs quantitative RT-PCR for the transporter gene
OCT6 performed With RNA extracted from peripheral blood
leukocytes, CD34+ cells and additional hematopoietic cell

SLC21A12
SLC21A13

28231
28230

LOC51737, OATP-E, POAT
OATPS, OATP-5

SLC21A14
SLC22A1
SLC22A2
SLC22A3
SLC22A4

53919
65 80
65 82
65 81
65 83

OATP-F
OCTl
OCT2
OCT3
OCTNl

55
SLC22

lines. Fresh discarded buffy coats that Were tWice sorted by

FACS using CD14 (monocytes), CD15 (granulocytes), CD3
(T-cells) and CD20 (B-cells). Purities of 99% or better Were

SLC22A5
SLC22A6
SLC22A7
SLC22A8
SLC22A9

65 84
9356
10864
9376

OCTN2, CDSP, SCD
NKT, OATl, OAT-1
NLT, OAT2, OAT-2
OAT3, OAT-3
OAT4, OAT-4

60

obtained. For peripheral WBC and sorted subsets, the

averageiSD represent pooled results from samples from 2
individuals performed in triplicate or quadruplicate. For
CD34-selected mobiliZed peripheral blood (MPB), the
results from each of 3 individuals are shoWn. For CD34
selected bone marroW (CD34+-BM), the results are from one
individual. OCT6 levels Were normalized to the expression of

OATP, OATPl, OATPlb,
OATP-A

FIG. 3. shoWs the normal tissue distribution of OCT6 RNA

gland; 2, thyroid; 3, adrenal; 4, pancreas; 5, ovary; 6, uterus;
7, prostate; 8, skins; 9, peripheral blood leukocytes; 10, bone

PGT

OAT-K1, OAT-K2
OATP2, OATP-2
LST-l, OATP-C
OATP3, OATP-3

65

The OAT and OCT carriers result in increased cellular

accumulation of their respective substrates, despite the fact

US 7,723,019 B2
6
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OCT1 and OCT2 are predominantly expressed in the kid

that they are carriers that mediate facilitative diffusion. For

ney and liver. These transporters are located on the basolateral

carriers, the degree of intracellular accumulation may not
exceed the extracellular concentration. However, the pres
ence of the carrier alloWs uptake in comparison to no uptake
in the absence of the carrier, and drugs that bind an intracel
lular target or Which are chemically modi?ed in the cells, e.g.,

surface of renal tubules and, therefore, play a role in the
removal of organic cations from the blood. OCT3 is most

abundantly expressed in placenta. In addition, other tissue
speci?c roles have been implicated for these transporters. As
noted above, OCTs may play a role in transport of endog
enous neuroleptic substrates, and OCT3 has been implicated
in the disposition of cationic neurotoxins and neurotransmit
ters in the brain (Wu, et al., J Biol Chem. 273: 32776-86,
1998). Dhillon et al. (Clin Pharrnacol Ther. 65: 205, 19996)
used RT-PCR folloWed by functional transport studies (TEA)
to identify OCT1 expression in a human mammary epithelial
cell line (MCF12A). Further, the OCT1 gene has been shoWn
to be up regulated in lactating mammary epithelial cells.

by phosphorylation or polyglutamylation, may be eliminated
from the substrate pool and not available for transport back
across the cellular membrane.

The ?rst ?ve members of the SLC22 family of transporters,

OCT1, OCT2, OCT3, OCTN1, and OCTN2, have been char
acteriZed as organic cation transporters. The uptake of many

cations, such as tetraethylammonium (TEA), N-l-methylni
cotineamide (NMN), choline, procainamide, amantadine and
morphine are mediated by these polyspeci?c transporters. In
general, these transporters are potential-dependent, but inde
pendent of sodium and proton gradients. These genes are all

The OCTN1 gene, cloned from a cDNA, shoWs sequence

similarity to organic cation transporter genes, Which is highly
expressed in kidney as Well as trachea, bone marroW and fetal

characterized by the presence of 11 or 12 transmembrane

domains, as predicted by hydrophobicity analysis, and all

20

have a large hydrophilic loop betWeen transmembrane
domain (TMD) 1 and TMD2.

cation antiporter functioning at the epithelial apical mem

brane. The uptake of pyrilamine, quinidine, verapamil and

OCT substrates are shoWn beloW in Table 2. Tetraethyl

ammonium (TEA) is the classic substrate for OCT transport
ers. In addition, OCT1, OCT2 and OCT3 transport 1-methyl
4-phenylpyridinium (MPP). Compared to OCT2, OCT1 has a

25

OCTN2 is more closely related to OCTN1 than to OCT1,
30

transporters include dopamine, histamine, epinephrine and

norepinephrine, acetylcholine and 5-hydroxytryptamine
(Burckhardt, et al., Am J Physiol Renal Physiol. 278: F853
66., 2000.), suggesting an important role for these transport

35

ers in the central nervous system, in addition to their role in

hepatic and renal clearance. Interestingly, despite its cationic

OCT2 and OCT3 (Biochem Biophys Res Commun. 246:
589-95, 1998). Transfection of OCTN2 has demonstrated its
role in the transport of TEA and carnitine. OCTN2-mediated
transport of TEA is sodium independent, Whereas transport of
carnitine is sodium-dependent. The role of sodium in
OCTN2-mediated carnitine transport not only involves the
electrogenic gradient, but the presence of sodium also alters
the a?inity of OCTN2 for carnitine. Germline mutations of
OCTN2 result in primary carnitine de?ciency, a syndrome of

progressive cardiomyopathy and skeletal myopathy. The

nature, recent studies have identi?ed cimetidine as a selective

inhibitor, but not a substrate for several organic cation trans

L-carnitine Were increased by expression of OCTN1 inXeno
pus oocytes.

Another OCT protein family member, OCTN2, cloned
from a human placental trophoblast cell line, is expressed
Widely in human tissues including kidney, placenta and heart.

higher a?inity for some cations (for example mepiperpheni
dol and procainamide), a similar a?inity for others (for
example, decynium 22 and quinidine), and a loWer a?inity for
corticosterone (See Koepsell et al., Ann. Rev. Physiol. 60:
243-266, 1998.). OCT3 is an electrogenic transporter for
TEA and guanidine. Other physiologic substrates for OCT

liver. Recombinant OCTN1 expressed in mammalian cells
exhibited saturable uptake of TEA that Was pH sensitive.
Several others suggest that OCTN1 is a renal proton/ organic

40

symptoms associated With this syndrome are thought to result

not only from generaliZed carnitine de?ciency from
decreased renal carnitine reabsorbtion, but also from inability

porters, including rOCT1, rOCT2, rOCT3, hOCTNl, and
hOCTN2.

of cardiac and skeletal myocytes, Which ordinarily express
OCTN2, to accumulate camitine. This syndrome demon

TABLE 2

45

strates that tissue-speci?c OCT-mediated transport is essen

tial for accumulation of required cations in speci?c tissues.

OCT Substrates

The present invention identi?es a neW transport protein in
Common

Name

Gene Name

Cell Type

Substrate

OCT1

SLC22A1

HeLa

TEA

OCT1

SLC22A1

Xenopus

MPP

OCT2

SLC22A2

Xenopus

Norepinephrine

1900

OCT2

SLC22A2

Xenopus

Histamine

1300

OCT2

SLC22A2

Xenopus

Dopamine

390

OCT2

SLC22A2

Xenopus

Serotonin

80

OCT2

SLC22A2

HEK293

MPP

OCT2
OCT2
OCT2

SLC22A2
SLC22A2
SLC22A2

HEK293
Xenopus
Xenopus

Dopamine
Amantadine
Memantine

OCT3
OCT3
OCTN1
OCTN2
OCTN2
OCTN2

SLC22A3
SLC22A3
SLC22A4
SLC22A5
SLC22A5
SLC22A5

HeLa
HRPE
Fibroblasts
HEK293
HEK293
HEK293

TEA
MPP
L-Camitine
L-Camitine
L-Camitine
D-Carnitine

OCTN2
OCTN2
OCTN2

SLC22A5
SLC22A5
SLC22A5
SLC22A5

HEK293
Xenopus
Xenopus
JAR

Acetyl-L-carnitine
L-Camitine
D-Carnitine

OCTN2

L-Camitine

the OCT family, OCT6, preferentially expressed in leukemia

KT (uM)
229

50

14. 6

16

and treatment of hematologic malignancies.
As used herein, the term “antibody” refers to an immuno
globulin molecule With a speci?c amino acid sequence
55

330
27
34

evoked in by an antigen, and characterized by reacting spe
ci?cally With the antigen in some demonstrable Way.
As used herein, the term “carrier” refers to a diluent, adju
vant, excipient, or vehicle With Which the compositions of the

2500
47
6. 6
4.34
4.3
10.9

8.5
4. 8
98
3.5

cell lines, leukemia blast cells and CD34+ cells. The cell
surface localiZation and the transporter function of the OCT6
gene product suggest its usefulness as a target in the diagnosis

present invention are administered.

As used herein, “compound” refers to any agent, chemical,
substance, or substrate, Whether organic or inorganic, or any

protein including antibodies, peptides, polypeptides, pep
toids, and the like.
As used herein, the term cytotoxin” or cytoxic agent
65

includes any speci?c substance, Which may or may not be
antibody, that inhibits or prevents the functions of cells,
causes destruction of cells, or both.

US 7,723,019 B2
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As used herein, the term “derivative” refers to something

OCT6 (SEQ ID NO:1) Was ?rst identi?ed as a potential

produced by modi?cation of something pre-existing; for

OCT gene by assembling and sequencing ESTs as described
in Example 1 (amino acid sequence of OCT6 is SEQ ID
NO:2). The gene sequence proved to be identical to the

example, a substance or chemical compound that may be
produced from another substance or compound of similar
As used herein, the term “fragment” refers to a part of a

recently submitted cDNA OKBl (GenBank AF268892) sub
mitted by M. Okabe and T. Abe, incorporated herein in its

larger entity, said larger entity comprising by non-limiting

entirety. It is also contained Within the submitted BAC clone

structure in one or more steps.

example, an antibody, compound or substance.

CTA-331P3 (SEQ ID NO: 3) (GenBank AC002464) located

As used herein, the term “leukemia blast” or “leukemic

at chromosome 6q21, incorporated herein in its entirety. The

blast” refers to lymphoblasts, the abnormal immature White 10 gene has a predicted protein structure typical of transport
blood cells associated With leukemia.
proteins With tWo groups of six transmembrane domains

As used herein, the term “monoclonal antibody” is not
limited to antibodies produced through hybridoma technol-

separated by a hydrophilic region (FIG. 1A). CLUSTALW
alignment produced a dendrogram shoWing the phylogenic

ogy. The term “monoclonal antibody” refers to an antibody

relationship betWeen OCT6 and other OAT and OCT proteins

that is derived from a single clone, including any eukaryotic, 15 (FIG. 1B). This dendrogram suggests that the distinction
prokaryotic, or phage clone, and not the method by Which it is
produced.
As used herein, the term “pharmaceutically acceptable carrier” refers to a carrier that may be administered to a subject,

betWeen OAT and OCT genes, based on functional studies,
obscures the common origin of both families of transporters.
The actual CLUSTALW alignment of these genes is shoWn in
FIG. 2 and demonstrates multiple regions of conservation

together With one or more liver protecting agents and one or 20 among all of these genes.

more mushroom poWder or extract of the present invention,
and Which does not destroy the pharmacological activity
thereof and is nontoxic When administered in doses su?icient

Next, according to the methods described in Example 3,
quantitative RT PCR analysis of the expression of OCT6 Was
performed, along With the expression of other OCT genes, in

to deliver a therapeutic amount of the compound.
50 cell lines. The results are shoWn in Table 3. The tWo highest
As used herein, the term “substrate” refers to a substance, 25 expressing cell lines for OCT6 in this panel Were tWo leuke

compound, agent, antibody or derivatives and/or fragment
thereof, acted upon by the OCT6 transporter protein (e.g., a
substance thatistaken acrossthe cellular membrane by action
of the OCT6 transporter protein).

mia cell lines, HL60, a human promyelocytic leukemia cell
line, and MOLT4, a human acute lymphoblastic leukemia
(T-cell) cell line. There Was only a loW level of expression
detected in most of the other cell lines.
TABLE 3
OCT expression in 50 cell lines ofthe NCI Drug Screen

No. Cell Line

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

CCRF-CEM
HL-60
K-562
MOLT-4
RPMI-8226
SR
A549/ATCC
HOP-62
NCI-H226
NCI-H23
NCI-H460
COLO205
HCC-2998
HCT-116
HCT-15
HT-29
KM-12
SW-620
SF-268
SF-295
SF-539
SNB-75
U251
LOCIMVI
MALME-3M
M14
SK-MEL-2
SK-MEL-5
UACC-257
IGROVl
OVCAR-3
OVCAR-4
OvCAR-5
OVCAR-8
SK-OV-3
A498
ACHN
CAKI 1

source

Leukemia
Leukemia
Leukemia
Leukemia
Leukemia
Leukemia
Lung cancer
Lung cancer
Lung cancer
Lung cancer
Lung cancer
Colon Ca.
Colon Ca.
Colon Ca.
Colon Ca.
Colon Ca.
Colon Ca.
Colon Ca.
CNS Tumor
CNS Tumor
CNS Tumor
CNS Tumor
CNS Tumor
Melanoma
Melanoma
Melanoma
Melanoma
Melanoma
Melanoma
Ovarian Ca.
Ovarian Ca.
Ovarian Ca.
Ovarian Ca.
Ovarian Ca.
Ovarian Ca.
Renal Ca.
Renal Ca.
Renal Ca.

OCT1

OCT2

OCT3

OCTN 2

OCT6

0.7
0.5
1.4
0.1
2.8
1.9
1.7
0.8
4.8
0.5
0.7
4.9
1.5
1.7
0.9
1.9
0.6
1.0
0.4
0.5
0.5
0.8
0.8
2.9
1.5
1.9
2.1
2.6
3.2
4.9
1.4
2.6
3.5
1.1
3.9
2.2
1.1
3.5

0.7
1.3
1.2
1.1
2.0
1.1
1.2
4.8
0.5
0.7
1.0
5.3
1.0
2.1
1.7
1.2
1.0
2.6
0.8
1.2
0.6
1.8
0.9
2.1
1.5
1.4
1.9
1.5
3.6
5015
0.1
1.4
2.7
1.0
1995
13.4
1.1
2.5

0.2
0.0
0.2
0.5
0.1
0.0
161
0.6
0.1
0.0
0.0
30.9
0.0
0.1
0.1
18.1
12.2
40.4
0.0
0.2
2.3
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0
17.9
0.0
0.0
105
0.0
9.2
180
0.7
4.8

0.1
0.4
1.4
0.6
3.7
0.3
4.3
2.4
21.1
0.3
1.7
2.2
2.6
2.8
3.5
1.5
0.7
1.9
0.9
1.1
0.2
0.6
0.6
0.4
2.3
1.9
2.2
1.9
1.1
1.8
2.2
8.9
10.0
0.8
8.5
4.7
1.2
1.8

5.7
716
5.2
46.8
6.02
2.6
1.2
4.1
4.8
5.2
1.8
3.6
5.4
9.7
4.2
1.5
2.1
3.7
2
2.5
5.3
2.3
7.4
3.6
3
4.7
3.9
2.7
5.4
2.5
14
3.4
4.8
1.6
9.8
1.3
1.1
2.8
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TABLE 3-continued
OCT expression in 50 cell lines ofthe NCI Drug Screen
No. Cell Line

source

39
40
41
42
43
44
45
46
47
48
49
50

Renal Ca.
Renal Ca.
Renal Ca.
Prostate Ca.
Prostate Ca.
Breast Ca.
Breast Ca.
Breast Ca.
Breast Ca.
Breast Ca.
Breast Ca.
Breast Ca.

RXF-393
TK-lO
UO-31
PC-3
DU-145
MCF-7
NCI/ADR-RES
MDA-MB-231
HS578T
MDA-MB-435
BT-549
T-47D

OCT1

OCT2

OCT3

OCTN2

OCT6

1.7
3.6
4.4
2.1
1.1
0.8
1.4
1.2
1.0
1.9
1.2
0.7

1.2
5.0
1.6
0.8
1.1
1.8
1.3
0.4
1.5
0.6
0.8
1.1

3.0
16.8
31.2
9.6
3.4
0.0
1.1
3.9
0.0
0.1
0.1
0.1

0.6
2.5
1.2
3.3
1.6
10.4
2.0
4.8
1.2
0.7
0.3
4.2

1.2
8
2.3
4.7
3
3.5
2.1
1.8
8.3
2.7
2.6
8.7

OCT6 is unique among the known members of OCT and 20
OAT genes because of its pattern of tissue distribution. The

TABLE 4

pattern of expression of the OCT6 gene in the 50 cell lines

I

suggested that its expression might be restricted to hematopoietic tissues. The restricted pattern of expression observed 25
for OCT6 also suggests that therapies using OCT6-speci?c
.
.
. .
substrates are unl1kely to have W1despread tox1c1ty to normal
tissues. Therefore, We examined OCT6 expression in a cDNA

salnple Number
1

2
3
4

panel representing a Wide cross-section of normal tissues
.

I

H?pwp?

.

Description
, ,
CML, blast cr1s1s
CML, blast crisis
CML, stable phase
CMhPIObablY Stable Phase

accordmg to the methods of Example 4 (FIG. 3). Th1s study 30

5

6

ALL

revealed that OCT6 RNA levels are highest in testis and fetal

7

ALL

liver, With loWer but detectable levels in peripheral blood

3

AML

leukocytes and bone marroW. Since fetal hematopoiesis

1g

25:

occurs in the liver, it is possible that the fetal liver sample may
have included both hepatocytes and hematopoietic cells. 35

11
12

ALL
AML

OCT6 RNA levels Were also barely detectable in pancreatic

3

2g:

and adrenal tissue. Unlike other OCT genes, expression Was

15

AML

not detectable in liver, kidney or placenta.

16

ALL, biphenotypic

To determine Whether OCT6 RNA expression in hemato- 40

CML, accelerated phase

i;

251 blph?notyplc

poietic cells Was lineage-speci?c, leukocytes Were sorted

19

AML, M2

from discarded buffy coat specimens by How cytometry, and

20

AML, M2

.

.

.

21

AML, M4

expression according to the methods described in Example 5.

23

AML, M1

OCT6 expression Was also examined in a population of 45
CD34+ cells. As can be seen in FIG. 4, the expression of

24
25

AML
AML’ M4

purl?ed subpopulat1ons Were exammed for OCT6 RNA

OCT6 Was highly enriched in CD34+ cells in comparison to
the other cell populations. Also, signi?cant levels of OCT6
expression (relative to MOLT4) Were found in other hemato-

22

AML, M4

Due to the OCT6 protein’s leeatiOn On the Cellular mem
hrahe and its fhhetleh a5 ah intracellular transporter, the

poietic Cell lines; U937’ a human histiocytic lymphoma Cell 50 OCT6 transporter protein has been identi?ed as a therapeutic

line; THP-l, a human acute monocytic leukemia cell line;
KGJ’ a human erythroleukemia Cell line; and MV_4_11’ a

human biphenotypic (B_Ce11 and myelomonocytic) leukemia
C en line‘

,

,

,

,

The hlgh levels “OCT6 RNA In some leukemla Cell hnés
and CD34+' cells also ra1sed the questlon as to Whether th1s

target Basle Pnhclples efeellular Pharmacology Suggest that
increase 1n mtracellular accumulat1on W111 lead to mcreased

mtracellular effect. Eor ant1cancer drugs, th1s pr1nc1ple has

been stud1ed extens1vely 1n the context of l1poph1l1c drugs,

55 Which require no speci?c mechanism for cellular uptake, and

export pumps such as the product of the multidrug resistance
gene’ MDRL Whose overexpression of MDRI leads to

gene Was hlghly expressed In actual leukemlas' To address

increased cellular resistance by decreasing intracellular con

thls issue: the RNA levels of OCT6 lh 25 Samples efPel‘lPh'

centrations of drug (Moscow, J. A., Schneider, E. S., Ivy, S. P.,

eral leukemic cells Were measured according to the methods 60 and COWans K_ H Multidrug resistance; In; H M_ pingdos D
set out in Example 6. The FAB classi?cation of these samples
L, Longo, and B, A, Chabner (eds), Cancer chemotherapy
are shoWn in Table 4. These results are shoWn in FIG. 5, and
and biological response modi?ers. Annual 17. NeW York:

demonstrate that the majority of specimens contained RNA
Elsevier, 1997). The same principle applies to charged,
levels for OCT6 that exceeded the level found in MOLT4 cell
hydrophilic drugs of the present invention, except that the
line, the second highest expressing cell line among those 65 determinants of sensitivity depend on uptake as opposed to
e?llux. As such, cells overexpressing an OCT6 transporter are
examined, and exceed by orders of magnitude the levels
likely to be highly sensitive to cytotoxic OCT6 substrates.
found in placenta, kidney and liver.

US 7,723,019 B2
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Drug Screening

at the linker sections of nucleosomes to give rise to fragments

Accordingly, the present invention provides methods for

equivalent to single and multiple nucleosomes. When these
DNA fragments are subjected to gel electrophoresis, they

screening potential substrates of, and potential therapeutic
agents against hematological malignancies like leukemia that

reveal a series of DNA bands Which are positioned approxi

overexpress, the OCT6 transporter. In particular, potential

mately equally distant from each other on the gel. The siZe

therapeutic agents are screened for the ability to be a substrate

difference betWeen the tWo bands next to each other is about

recogniZed by an OCT6 transporter protein. Preferably,

the length of one nucleosome (i.e., 20 base pairs). This char

potential substrates are screened for the ability to confer
cytotoxic effects on a cell overexpressing OCT6 transporter
protein. More preferably, agents are screened for the ability to

acteristic display of the DNA bands is called a DNA ladder
and it indicates apoptosis of the cell. Apoptotic cells can be
identi?ed by ?oW cytometric methods based on measurement
of cellular DNA content, increased sensitivity of DNA to

preferentially cause cellular uptake into, and cell death of,
cells overexpressing the OCT6 transporter. Most preferably,

denaturation, or altered light scattering properties. These

the agents are screened for the ability to cause cell death of
cancer cells such as leukemia overexpressing the OCT6 trans
porter as compared to normal cells.

plation of the invention.

A method for screening potential substrates of the OCT6
transporter protein comprises providing a cell or cell line

and can be detected by any means knoWn in the art. In one

methods are Well knoWn in the art and are Within the contem

Abnormal DNA breaks are also characteristic of apoptosis

Which expresses OCT6 and a test compound, incubating the
test compound and cell line and analyZing the cell or cell line
to determine if there Was a cellular in?ux of the test com

20

pound. Analysis of the cell line to determine Whether cellular

embodiment, DNA breaks are labeled With biotinylated
dUTP (b-dUTP). Cells are ?xed and incubated in the presence
of biotinylated dUTP With either exogenous terminal trans
ferase (terminal DNA transferase assay; TdT assay) or DNA

polymerase (nick translation assay; NT assay). The biotiny

uptake of the test compound occurred canbe accomplished by

lated dUTP is incorporated into the chromosome at the places

any means knoWn in the art. For example, a test compound
can be tagged With a detectable label prior to contact With a
cell and then observed under microscopy or by other means

Where abnormal DNA breaks are repaired, and are detected

With ?uorescein conjugated to avidin under ?uorescence
25

for its location. Non-limiting examples of labels include
green ?uorescent protein, alkaline phosphatase, horseradish
peroxidase, rease, f3-galactosidase, CAT, luciferase, an
immunogenic tag peptide sequence, an extrinsically activat
able enzyme, an extrinsically activatable toxin, an extrinsi

microscopy.
Kits
The present invention provides kits that can be used in the
above screening methods. In one embodiment, a kit com

30

cally activatable ?uor, an extrinsically activatable quenching
agent, a radioactive element or an antibody.

A method for screening candidate anti-cancer agents com

prises determining the viability of a mammalian cell Which
expresses OCT6 incubated in the presence and absence of a

35

test compound and identifying the test compound as a poten
tial anti-leukemia agent if there is a cellular uptake of the test
compound and cell death. Analysis of cell viability can be
accomplished by any means knoWn in the art.
It is Well knoWn in the art that viability of a cell can be

40

prises a substantially isolated polypeptide comprising an
OCT6 epitope Which is speci?cally immunoreactive With
only test compound(s) that are substrates of the OCT6 trans
porter protein. Binding of a test compound to the OCT6
epitope is indicative that the test compound is a OCT6 sub
strate. In another embodiment, a kit comprises a cell line that
overexpresses an OCT6 transporter protein. Binding and/or
cellular uptake of a test compound via the OCT6 protein is
indicative that the test compound is a OCT6 substrate. Pref
erably, the kits of the present invention further comprise a
control compound or antibody Which does not react With the

determined by contacting the cell With a dye and vieWing it

OCT6 transporter protein. In another speci?c embodiment,

under a microscope. Viable cells can be observed to have an

the kits of the present invention contain a means for detecting
the binding of a test compound to an OCT6 epitope and/or
cellular uptake of a test compound. For example, the test
compound may be conjugated to a detectable substrate such
as a ?uorescent compound, an enzymatic substrate, a radio

intact membrane and do not stain, Whereas dying or dead cells

having “leaky” membranes do stain. Incorporation of the dye
by the cell indicates the death of the cell. The most common

45

dye used in the art for determining viability is trypan blue.
Viability of cells can also be determined by detecting DNA

active compound or a luminescent compound, or a second

synthesis. Cells can be cultured in cell medium With labeled

antibody Which recogniZes the ?rst antibody may be conju

nucleotides (e. g., 3H thymidine). The uptake or incorporation

gated to a detectable substrate.

of the labeled nucleotides indicates DNA synthesis and cell

50

viability. In addition, colonies formed by cells cultured in
medium indicate cell groWth and is another means to test

viability of the cells.
Identi?cation and/ or observation of cells undergoing apo

ptosis can be another method of determining cell viability.
Apoptosis is a speci?c mode of cell death recogniZed by a
characteristic pattern of morphological, biochemical, and

55

shrunken, and rounded; they also can be observed to become
60

involve a characteristic pattern of condensation of chromatin

and cytoplasm Which can be readily identi?ed by microscopy.

The hallmark of apoptosis is the endonucleolysis, a

molecular change in Which nuclear DNA is initially degraded

als, bioluminescent materials, radioactive materials, positron
emitting metals using various positron emission tomogra
phies, nonradioactive paramagnetic metal ions, immuno
genic tag peptide sequences, extrinsically activatable toxins,
extrinsically activatable quenching agents, or antibodies.
Non-limiting examples of suitable enZymes include horse

When stained With a DNA-binding dye, such as H33258,

apoptotic cells display classic condensed and punctate nuclei
instead of homogeneous and round nuclei.

Which can be conjugated to antibodies for use as diagnostics

according to the present invention. Further non-limiting
examples of detectable substances include various enZymes,
prosthetic groups, ?uorescent materials, luminescent materi

molecular changes. Cells going through apoptosis appear
detached from culture dish. Thermophological changes

The detectable substance may be coupled or conjugated

either directly to the test compound (or fragment thereof) or
indirectly, through an intermediate (such as, for example, a
linker knoWn in the art) using techniques knoWn in the art.
See, for example, U.S. Pat. No. 4,741,900 for metal ions

65

radish peroxidase, alkaline phosphatase, beta-galactosidase,
or acetylcholinesterase; examples of suitable prosthetic
group complexes include streptavidin/biotin and avidin/bi

US 7,723,019 B2
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otin; examples of suitable ?uorescent materials include

Monoclonal Antibodies and T-Cell Hybridomas 563-681

(Elsevier, N.Y., 1981) (said references incorporated by refer

umbelliferone, ?uorescein, ?uorescein isothiocyanate,
rhodamine, dichlorotriaZinylamine ?uorescein, dansyl chlo

ence in their entireties).
The present invention further encompasses antibodies or

ride or phycoerythrin; an example of a luminescent material

sitions for the treatment of hematolo gical malignancies. Non

fragments thereof conjugated to a diagnostic or therapeutic
agent. The antibodies can be used diagnostically to, for
example, monitor the development or progression of a tumor
as part of a clinical testing procedure to, e.g., determine the
e?icacy of a given treatment regimen. Detection can be facili
tated by coupling the antibody to a detectable substance.
Examples of detectable substances include various enZymes,

limiting exemplary hematological malignancies include, but

prosthetic groups, ?uorescent materials, luminescent materi

are not limited to, Hodgkin’s disease, leukemia such as, acute

lymphoid (lymphocytic or lymphoblastic) leukemia (ALL),

als, bioluminescent materials, radioactive materials, positron
emitting metals using various positron emission tomogra

acute myeloid (myelogenous or myeloblastic) leukemia

phies, and nonradioactive paramagnetic metal ions. The

(AML), acute lymphoid leukemia, biphenotypic (ALL,

detectable substance may be coupled or conjugated either

biphentoypic), acute undifferentiated leukemia (AUL),
chronic myeloid (myelogenous or granulocytic) leukemia

through an intermediate, such as, for example, a linker knoWn

includes luminol; examples of bioluminescent materials
include luciferase, luciferin, and aequorin; and examples of
suitable radioactive material include 125I, 131I, 1 11In or 99Tc.

Immunogenic Compositions
The present invention also provides immunogenic compo

(CML), erythroleukemia, granuloxytic leukemia, lymphoma,
monocytic leukemia, myleoma, myelomonocytic leukemia,
myelodysplastic syndromes, non-Hodgkin lymphoma, pro

directly to the antibody (or fragment thereof) or indirectly,
in the art, using techniques knoWn in the art. (See, for
20

granulocytic leukemia.
According to the invention immunogenic compositions for

the present invention.) Examples of suitable enZymes include

horseradishperoxidase, alkaline phosphatase, beta-galactosi

the treatment of hematological malignancies comprise a sub

strate recogniZed by an OCT6 transporter protein. Preferably,

25

the substrate is a compound that binds selectively or speci?
cally to a OCT6 transporter protein. In a preferred embodi
ment, the compound binds selectively to the OCT6 trans
porter protein encoded by a nucleotide sequence of SEQ ID
NO: 1. The compound may be a cytotoxin or coupled or con

ride or phycoerythrin; an example of a luminescent material
30

gated to a therapeutic moiety such as a cytotoxin, e.g., a
cytostatic or cytocidal agent, a therapeutic agent or a radio

effective amount of a compound, and a pharmaceutically

active metal ion, e.g., alpha-emitters such as, for example,
213 Bi. Non-limiting examples include paclitaxol, cytochala

acceptable carrier.
Cell surface proteins like the OCT6 transporter can be

bodies are substrates of the OCT6 protein. The antibodies
may be polyclonal antibodies or monoclonal antibodies.
Polyclonal antibodies to an antigen-of-interest can be pro

sin B, gramicidin D, ethidium bromide, emetine, mitomycin,
40

thereof. Therapeutic agents include, but are not limited to,
45

50

vants may be used to increase the immunological response,
depending on the host species, and include but are not limited

to, Freund’s (complete and incomplete), mineral gels such as
aluminum hydroxide, surface active substances such as lyso

lecithin, pluronic polyols, polyanions, peptides, oil emul
sions, keyhole limpet hemocyanins, dinitrophenol, and

etoposide, tenoposide, vincristine, vinblastine, colchicin,
doxorubicin, daunorubicin, dihydroxy anthracin dione,
mitoxantrone, mithramycin, actinomycin D, l-dehydrotest
osterone, glucocorticoids, procaine, tetracaine, lidocaine,
propranolol, and puromycin and analogs or homologs

duced by various procedures Well knoWn in the art. For
example, a polypeptide of the invention can be administered
to various host animals including, but not limited to, rabbits,
mice, rats, etc. to induce the production of sera containing

polyclonal antibodies speci?c for the antigen. Various adju

includes luminol; examples of bioluminescent materials
include luciferase, luciferin, and aequorin; and examples of
suitable radioactive material include 125 I, 131I, 11 1In or 99Tc.
Further, an antibody or fragment thereof may be conju

positions. Such compositions comprise a therapeutically

knoWn methods in the art against the external epitope of
OCT6 transporter protein. In a preferred embodiment, anti

dase, or acetylcholinesterase; examples of suitable prosthetic
group complexes include streptavidin/biotin and avidin/bi
otin; examples of suitable ?uorescent materials include

umbelliferone, ?uorescein, ?uorescein isothiocyanate,
rhodamine, dichlorotriaZinylamine ?uorescein, dansyl chlo

jugated With a cytoxic agent. Preferably the cytoxin or cyto
toxic agent is a chemotherapeutic agent.
The present invention also provides pharmaceutical com

utiliZed in antibody-based targeting strategies. In still another
aspect of the invention, antibodies can be developed by

example, US. Pat. No. 4,741,900 for metal ions Which can be
conjugated to antibodies for use as diagnostics according to

antimetabolites (e.g., methotrexate, 6-mercaptopurine,
6-thioguanine, cytarabine, 5-?uorouracil decarbaZine), alky
lating agents (e.g., mechlorethamine, thioepa chlorambucil,
melphalan, carmustine (BSNU) and lomustine (CCNU),
cyclothosphamide, busulfan, dibromomannitol, streptoZoto
cin, mitomycin C, and cis-dichlorodiamine platinum (II)
(DDP) cisplatin), anthracyclines (e.g., daunorubicin (for
merly daunomycin) and doxorubicin), antibiotics (e.g., dac

tinomycin (formerly actinomycin), bleomycin, mithramycin,
55

and anthramycin (AMC)), and anti-mitotic agents (e.g., vin
cristine and vinblastine).

potentially useful human adjuvants such as BCG (bacille

The conjugates of the invention can be used for modifying
a given biological response such as inducing cell death for the

Calmette-Guerin) and corynebaclerium parvum. Such adju

treatment and prevention of hematological malignancies like

vants are also Well knoWn in the art.

Monoclonal antibodies can be prepared using a Wide vari

60

For example, the drug moiety may be a protein or polypeptide
possessing a desired biological activity for inducing cell

ety of techniques knoWn in the art including the use of hybri
doma, recombinant, and phage display technologies, or a
combination thereof. For example, monoclonal antibodies

death. Such proteins may include, for example, a toxin such
as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin;

can be produced using hybridoma techniques including those
knoWn in the art and taught, for example, in HarloW et al.,

Antibodies: A Laboratory Manual, (Cold Spring Harbor
Laboratory Press, 2nd ed. 1988); Hammerling, et al., in:

leukemia. The therapeutic agent or drug moiety is not to be
construed as limited to classical chemical therapeutic agents.
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a protein such as tumor necrosis factor, a-interferon, .beta.

interferon, nerve groWth factor, platelet derived groWth fac
tor, tissue plasminogen activator, an apoptotic agent, e.g.,

US 7,723,019 B2
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TNF-alpha, TNF-beta, AIMI (See, International Publication

Where the composition is to be administered by infusion, it

No. WO 97/33899), AIM II (See, International Publication
No. WO 97/34911), Fas Ligand (Takahashi et al., Int. Immu
nol., 6: 1 567-1574 (1994)), VEGI (See, International Publica

pharmaceutical grade Water or saline. Where the composition
is administered by injection, an ampoule of sterile Water for

tion No. W0 99/ 23 1 05), a thrombotic agent or an anti-angio

injection or saline can be provided so that the ingredients may
be mixed prior to administration.

can be dispensed With an infusion bottle containing sterile

genic agent, e.g., angiostatin or endostatin; or, biological
response modi?ers such as, for example, lymphokines, inter
leukin-1 (“IL-1”), interleukin-2 (“IL-2”), interleukin-6 (“IL

The compounds of the invention can be formulated as

neutral or salt forms. Pharmaceutically acceptable salts
include those formed With anions such as those derived from

6”), granulocyte macrophage colony stimulating factor
(“GM-CSF”), granulocyte colony stimulating factor (“G

hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc.,
and those formed With cations such as those derived from

CSF”), or other groWth factors.

sodium, potassium, ammonium, calcium, ferric hydroxides,
isopropylamine, triethylamine, 2-ethylamino ethanol, histi

Therapeutic Treatment

dine, procaine, etc.

The present invention is further directed to methods for

The amount of the compound of the invention Which Will
be effective in the treatment, inhibition and prevention of
hematological malignancies can be determined by standard
clinical techniques. In addition, in vitro assays may option

preventing and treating hematological malignancies such as
leukemia. According to the invention, hematological malig
nancies comprise Without limitation, Hodgkin’s disease, leu
kemia such as, acute lymphoid (lymphocytic or lymphoblas

tic) leukemia (ALL), acute myeloid (myelogenous or

ally be employed to help identify optimal dosage ranges. The

myeloblastic) leukemia (AML), acute lymphoid leukemia,
biphenotypic (ALL, biphentoypic), acute undifferentiated
leukemia (AUL), chronic myeloid (myelogenous or granulo
cytic) leukemia (CML), erythroleukemia, granuloxytic leu

precise dose to be employed in the formulation Will also
depend on the route of administration, and the seriousness of
the disease or disorder, and should be decided according to

kemia, lymphoma, monocytic leukemia, myleoma,
myelomonocytic leukemia, myelodysplastic syndromes,
non-Hodgkin lymphoma, progranulocytic leukemia.

20

the judgment of the practitioner and each patient’s circum
stances. Effective doses may be extrapolated from dose-re
sponse curves derived from in vitro or animal model test
25

systems.

Methods of treatment of the present invention comprise
administering to a subject in need thereof an immunogenic

Various other delivery systems are knoWn and can be used
to administer a composition of the invention, e.g., encapsu

composition of the present invention. The compositions may

lation in liposomes, microparticles, microcapsules, recombi
nant cells capable of expressing the compound, receptor
mediated endocytosis (See, e.g., Wu and Wu, J. Biol. Chem.

be administered With a pharmaceutically acceptable carrier.
Such pharmaceutical carriers can be sterile liquids, such as

30

262:4429-4432 (1987)), construction ofa nucleic acid as part

Water and oils, including those of petroleum, animal, veg
etable or synthetic origin, such as peanut oil, soybean oil,

of a retroviral or other vector, etc. Methods of introduction

mineral oil, sesame oil and the like. Water is a preferred

include but are not limited to intradermal, intramuscular,

carrier When the pharmaceutical composition is administered
intravenously. Saline solutions and aqueous dextrose and
glycerol solutions can also be employed as liquid carriers,

ral, and oral routes. The compounds or compositions may be

particularly for injectable solutions. Suitable pharmaceutical
excipients include starch, glucose, lactose, sucrose, gelatin,
malt, rice, ?our, chalk, silica gel, sodium stearate, glycerol
monostearate, talc, sodium chloride, dried skim milk, glyc
erol, propylene, glycol, Water, ethanol and the like. The com

intraperitoneal, intravenous, subcutaneous, intranasal, epidu
35

mucocutaneous linings (e.g., oral mucosa, rectal and intesti
nal mucosa, etc.) and may be administered together With
other biologically active agents. Administration can be sys
40

temic or local. In addition, it may be desirable to introduce the

pharmaceutical compounds or compositions of the invention

position, if desired, can also contain minor amounts of Wet

into the central nervous system by any suitable route, includ

ting or emulsifying agents, or pH buffering agents. These
compositions can take the form of solutions, suspensions,

ing intraventricular and intrathecal injection; intraventricular
injection may be facilitated by an intraventricular catheter, for

emulsion, tablets, pills, capsules, poWders, sustained-release
formulations and the like. The composition can be formulated

administered by any convenient route, for example by infu
sion or bolus injection, by absorption through epithelial or
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example, attached to a reservoir, such as an Ommaya reser

as a suppository, With traditional binders and carriers such as

voir. Pulmonary administration can also be employed, e. g., by

triglycerides. Oral formulation can include standard carriers

use of an inhaler or nebuliZer, and formulation With an aero

such as pharmaceutical grades of mannitol, lactose, starch,
magnesium stearate, sodium saccharine, cellulose, magne
sium carbonate. etc. Examples of suitable pharmaceutical

soliZing agent.
In a speci?c embodiment, it may be desirable to administer
50

the pharmaceutical compounds or compositions of the inven
tion locally to the area in need of treatment; this may be

carriers are described in “Remington’s Pharmaceutical Sci
ences” by E. W. Martin. Such compositions Will contain a

achieved by, for example, and not by Way of limitation, local

therapeutically effective amount of the compound, preferably

infusion during surgery, topical application, e.g., in conjunc

in puri?ed form, together With a suitable amount of carrier so
as to provide the form for proper administration to the patient.
The formulation should suit the mode of administration.

tion With a Wound dressing after surgery, by injection, by
55

means of a catheter, by means of a suppository, or by means

of an implant, said implant being of a porous, non-porous, or

In a preferred embodiment, the composition is formulated

gelatinous material, including membranes, such as sialastic

in accordance With routine procedures as a pharmaceutical

membranes, or ?bers. Preferably, When administering a pro
tein, including an antibody, of the invention, care must be

composition adapted for intravenous administration to

taken to use materials to Which the protein does not absorb.

human beings. Typically, compositions for intravenous
administration are solutions in sterile isotonic aqueous buffer.
Where necessary, the composition may also include a solu
biliZing agent and a local anesthetic such as lignocaine to ease

pain at the site of the injection. Generally, the ingredients are
supplied either separately or mixed together in unit dosage
form, for example, as a dry lyophiliZed poWder or Water free

60

In another embodiment, the compound or composition can
be delivered in a vesicle, in particular a liposome (See Langer,
Science 249: 1527-1533 (1990); Treat et al., in Liposomes in
the Therapy of Infectious Disease and Cancer, LopeZ-Berest
ein and Fidler (eds.), Liss, NeW York, pp. 353-365 (1989);

65

LopeZ-Berestein, ibid., pp. 317-327; see generally ibid.)

concentrate in a hermetically sealed container such as an

In yet another embodiment, the compound or composition

ampoule or sachette indicating the quantity of active agent.

can be delivered in a controlled release system. In one

US 7,723,019 B2
17
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embodiment, a pump may be used (see Langer, supra; Sefton,
CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al.,
Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:
574 (1989)). In another embodiment, polymeric materials can
be used (see Medical Applications of Controlled Release,

The gene has a predicted protein structure typical of trans
port proteins With 2 groups of 6 transmembrane domains

separated by a hydrophilic region (FIG. 1A). The large hydro
philic region betWeen TMD1 and TMD2 is typical of OCT
and OAT genes and is presumed to be located on the outside

surface of the cell membrane. The OCT6 protein contains

Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974);
Controlled Drug Bioavailability, Drug Product Design and
Performance, Smolen and Ball (eds.), Wiley, NeW York
(1984); Ranger and Peppas, 1., Macromol. Sci. Rev. Macro

Which Will be described beloW in Methods. Of interest, the
protein sequence also contains a 22 amino acid leucine Zipper

mol. Chem. 23:61 (1983); see also Levy et al., Science 228:

motif, starting at amino acid 146, suggesting that there may be

potential sites for N-glycosylation and phosphorylation,

190 (1985); During et al., Ann. Neurol. 25:351 (1989);
HoWard et al., J. Neurosurg. 71:105 (1989)). In yet another

a physical interaction betWeen OCT6 and ion channels or

other membrane-associated proteins.
CLUSTALW alignment produced a dendrogram shoWing
the phylogenic relationship betWeen OCT6 and other OAT
and OCT proteins (FIG. 1B). This dendrogram suggests that

embodiment, a controlled release system can be placed in

proximity of the therapeutic target, i.e., the brain, thus requir
ing only a fraction of the systemic dose (see, e.g., Goodson, in
Medical Applications of Controlled Release, supra, vol. 2, pp.
115-138 (1984)).
In a speci?c embodiment Where the compound of the
invention is a nucleic acid encoding a protein, the nucleic acid
can be administered in vivo to promote expression of its
encoded protein, by constructing it as part of an appropriate
nucleic acid expression vector and administering it so that it
becomes intracellular, e.g., by use of a retroviral vector (see
US. Pat. No. 4,980,286), or by direct injection, or by use of
microparticle bombardment (e.g., a gene gun; Biolistic,
Dupont), or coating With lipids or cell-surface receptors or
transfecting agents, or by administering it in linkage to a
homeobox-like peptide Which is knoWn to enter the nucleus
(see e.g., Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864

the distinction betWeen OAT and OCT genes, based on func

tional studies, obscures the common origin of both families of
transporters. The actual CLUSTALW alignment of these
genes is shoWn in FIG. 2 and demonstrates multiple regions of
conservation among all of these genes.
20

Ware.

25

for expression, by homologous recombination.

BLAST searches of human ESTs in GenBank data base
30

The folloWing examples are presented for the illustrative

35

5'-coding region. All clones Were obtained from the IMAGE
tions. The sequences Were determined using ABI PrismTM
40

45

OCT6 Was ?rst identi?ed as a potential OCT gene by

peutics Program, NCI. Quantitative RT-PCR for detecting

bP), AA033971 (714 bp) and H70190 (474 bp) sequences

OAT-X transporter gene expression Was performed by using a

from three fetal liver IMAGE clones, 1656502, 429904 and
212935 respectively. IMAGE clone 1656502 (3', insert 1337

Roche LightCycler, Which uses real time ?uorescence detec
tion for quantitative measurement of PCR products. A gene

speci?c primerpair Was designed With Oligo 4.0 softWare and
55

American Type Culture Collection (Manassas, Va.). Each
clone Was sequenced in both directions. The sequences Were

determined using ABI PrismTM 377 DNA sequencer (Perkin
Elmer). Our assemblage proved to be identical to the recently
submitted cDNA OKBl (AF268892) submitted by M. Okabe
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and T. Abe. We have dubbed this gene OCT6 as OCTN1 and
OCTN2 may be considered as OCT4 and OCT5 respectively.

PCR reaction Was con?rmed by directly determining the
DNA sequence of the PCR product. First, cDNA Was synthe
siZed from total RNA using SuperScript First-Strand Synthe
sis System (GIBCO/BRL) in a 20 ul volume folloWing the
instructions supplied by the manufacturer. The cDNA treated

reaction condition, using 0.3 uM primer concentration, With

BAC clone CTA-331P3 (SEQ ID NO:3) (GenBank
exons that span 42 kb on the human genome, from nucleotide
79,570 to nucleotide 120490 on CTA-331P3.

purchased from Integrated DNA Technologies, Inc. (Cor
alville, IoWa) (F: 5'-GGCACATTTATTCACCAAGACCAG
3') (SEQ ID NO: 13) and (F: 5'-TGTGGACCTCAGCAG
CATTTGGAT-3') (SEQ ID NO:14). The speci?city of the

With RNAse H for 20 minutes at 370 C. and stored at —200 C.
Then, 2 ul of cDNA reaction Was ampli?ed in a standard PCR

The OCT6 gene (SEQ ID NO:1) is also contained Within
AC002464) located at chromosome 6q21. It is divided into 6

Quantitative RT-PCR of OCT6 RNA Levels in
Cancer Cell Lines
Total RNA isolated from 50 cell lines used in the NCI drug
screen program Was provided by the Developmental Thera

assembling and sequencing ESTs. BLAST searches of
human ESTs in GenBank data base identi?ed AI040384 (654

Were obtained from the IMAGE Consortium through the

377 DNA sequencer (Perkin-Elmer).

Example 3

OCT6 Nucleotide Sequence Identi?cation and

bp) ended the predicted 3' stop codon, Whereas IMAGE clone
429904 (5', insert 996 bp) and IMAGE clone 212935 (5',
insert 966 bp) aligned With the 5'-coding region. All clones

clones, 1656502, 429904 and 212935 respectively. IMAGE
clone 1656502 (3', insert 1337 bp) ended the predicted 3' stop
codon, Whereas IMAGE clone 429904 (5', insert 996 bp) and
IMAGE clone 212935 (5', insert 966 bp) aligned With the
Consortium through the American Type Culture Collection
(Manassas, Va.). Each clone Was sequenced in both direc

Example 1

Analysis

identi?ed AI040384 (654 bp), AA033971 (714 bp) and
H70190 (474 bp) sequences from three fetal liver IMAGE

EXAMPLES

purposes and it is to be understood that the present invention
is not limited to those precise embodiments, and that various
changes and modi?cations can be effected therein by one
skilled in the art Without departing from the scope and spirit of
the invention as de?ned by the appended claims.

Example 2
Molecular Cloning of OCT6

1868 (1991)), etc. Alternatively, a nucleic acid can be intro

duced intracellularly and incorporated Within host cell DNA

The hydropathy pro?le analysis, multiple sequence align
ments of amino acid sequences using CLUSTALW and the
phylogenetic tree Were all produced With MacVector soft
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the addition of SYBR Green I Dye. After 30 seconds denature

at 950 C., the ampli?cation reaction proceeded through 45-50
cycles of 950 C. denature for 0 second, 62-650 C. annealing

